免責聲明: 本站彙整 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公開資料,僅供一般參考,不構成醫療建議、診斷、治療建議或投資建議。

FDA 510(k)

簡易快篩COVID-19及流感A/B直測

K 號:K220963 · 2023-03-17

決定日期2023-03-17
產品代碼QOF
諮詢委員會MI (請提供完整的描述文本,以便進行翻譯。)
決定相當於

器材摘要

Simplexa COVID-19 & Flu A/B Direct is the device name listed in this FDA 510(k) record. The listed applicant is Diasorin Molecular, LLC. It received FDA 510(k) clearance on 2023-03-17 under 510(k) number K220963. The device is classified under product code QOF. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

常見問題

What is the Simplexa COVID-19 & Flu A/B Direct?

Simplexa COVID-19 & Flu A/B Direct is a medical device that received FDA 510(k) clearance on 2023-03-17. The listed applicant is Diasorin Molecular, LLC. The 510(k) number is K220963.

When did Simplexa COVID-19 & Flu A/B Direct receive FDA 510(k) clearance?

Simplexa COVID-19 & Flu A/B Direct received FDA 510(k) clearance on 2023-03-17, under 510(k) number K220963.

Who is the listed applicant for Simplexa COVID-19 & Flu A/B Direct?

The FDA 510(k) record lists Diasorin Molecular, LLC as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Simplexa COVID-19 & Flu A/B Direct?

The FDA product code for Simplexa COVID-19 & Flu A/B Direct is QOF.

相關臨床試驗

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

其他以 Diasorin Molecular, LLC 為申請人之記錄

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

查看所有 13 項裝置 →

相關器械(代碼:QOF)

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

官方來源

在 FDA 資料庫中查看 →

資料來源為 FDA Open API。如需最新且權威的資訊,請始終參閱官方記錄。

↑